Schizophrenia patients who were heavy cannabis users before their first psychotic episode showed fewer neurological signs and better cognitive performance than those who did not use heavily, suggesting a different pathway to illness.
Read this if you want to understand the complex relationship between cannabis use and psychosis, particularly whether cannabis-related schizophrenia is different from other forms.
Heavy pre-psychosis cannabis users had fewer neurological signs and better cognition than non-users with schizophrenia
What the researchers found
This study compared 34 schizophrenia patients who reported heavy cannabis use before their first psychotic episode with 27 patients who did not.
The results were counterintuitive: heavy pre-psychosis cannabis users showed significantly fewer neurological soft signs (subtle neurological abnormalities considered markers of early neurodevelopmental impairment) and better cognitive functioning across multiple domains including reaction time, episodic memory, and visuoconstructive abilities.
These findings held after controlling for alcohol and tobacco use. Age and gender did not significantly differ between groups.
The authors interpreted this as evidence that heavy pre-psychosis cannabis use may define a distinct phenotype of schizophrenia. Rather than cannabis simply adding neurotoxic damage on top of existing vulnerability, the pattern suggests cannabis-associated psychosis may represent a different route to schizophrenia that involves less neurodevelopmental impairment but where cannabis provides the additional push toward illness.
Why it matters
This study challenges the simple narrative that cannabis damages the brain and causes psychosis. Instead, it suggests there may be at least two pathways to schizophrenia: one driven primarily by neurodevelopmental impairment and one where cannabis triggers psychosis in people with relatively intact neurodevelopment.
The numbers in context
61 patients: 34 heavy pre-psychosis users, 27 non-heavy users. Heavy users showed significantly fewer neurological soft signs (p < 0.003) and better performance on reaction time (p = 0.03), episodic memory (p = 0.04), and visuoconstructive praxis (p = 0.03).
How the study worked
Cross-sectional study of 61 schizophrenia patients (34 heavy pre-psychosis cannabis users, 27 non-heavy users) at a University Hospital and Medical Center. Assessment included the Diagnostic Interview for Genetic Studies, Neurological Evaluation Scale (neurological soft signs), PANSS (psychopathology), and a neurocognitive battery measuring attention, memory, and executive functions.
What this study cannot tell us
Cross-sectional design cannot establish causality. Self-reported cannabis use before psychosis onset may be subject to recall bias. The sample size is relatively small. Patients with heavy cannabis use and better cognition may differ from non-users in unmeasured ways (intelligence, socioeconomic status).
How to read the evidence
Cross-sectional study with comprehensive neurological and cognitive assessment. Moderate because the sample size is small but the findings are well-controlled and clinically meaningful.
When this study was published
Published in 2017.
The bigger picture
If cannabis-associated schizophrenia represents a distinct phenotype, it could respond differently to treatment and have a different prognosis. This has implications for personalized psychiatry and for understanding the heterogeneity of schizophrenia.
Questions still open
- Do patients with cannabis-associated psychosis respond differently to antipsychotic treatment? Would they have developed psychosis without cannabis, or is cannabis the necessary trigger? Does this phenotype have a different genetic risk profile?
Common questions
Does cannabis cause brain damage that leads to schizophrenia?
Is cannabis-related psychosis different from other psychosis?
Read the original research
Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype?
European archives of psychiatry and clinical neuroscience, 267(7), 629-638
Citation
Mallet, Jasmina; Ramoz, Nicolas; Le Strat, Yann; Gorwood, Philip; Dubertret, Caroline. (2017). Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype?. European archives of psychiatry and clinical neuroscience, 267(7), 629-638. https://doi.org/10.1007/s00406-017-0767-0
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)